16 November 2012 | News | By BioSpectrum Bureau
Daiichi Sankyo seeks approval to manufacture Inavir Dry Powder Inhaler in Japan
Good news for influenza patients - Daiichi Sankyo to launch Inavir Dry Powder Inhaler in Japan
Singapore: Daiichi Sankyo submitted an application for a partial label change in Japan to manufacture and market the influenza anti-viral product Inavir Dry Powder Inhaler (laninamivir octanoate hydrate) for prevention of influenza infection.
Inavir is a long-acting neuraminidase inhibitor with therapeutic efficacy after a single dosage, which was developed and produced by Daiichi Sankyo. The drug received approval for manufacture and marketing for treatment of influenza A and B viruses in Japan on September 10, 2010, and was launched on October 19, 2010.
The safety and efficacy of Inavir in the prevention of influenza virus infection among household contacts of patients with influenza A or B virus infection was confirmed in phase III clinical trials. Daiichi Sankyo firmly believes that this new influenza prevention option will widely contribute to the health of patients and society.